La traduzione di questa pagina è sperimentale e in fase di sviluppo. Siamo lieti di ricevere vostro !

Immunovia Gestione

Gestione criteri di controllo 1/4

Al momento non disponiamo di informazioni sufficienti sull'amministratore delegato.

Informazioni chiave

Philipp Mathieu

Amministratore delegato

n/a

Compenso totale

Percentuale dello stipendio del CEO	n/a
Mandato del CEO	less than a year
Proprietà del CEO	0.009%
Durata media del management	less than a year
Durata media del Consiglio di amministrazione	5.5yrs

Aggiornamenti recenti sulla gestione

Recent updates

AMMINISTRATORE DELEGATO

Philipp Mathieu

less than a year

Mandato

Mr. Philipp Mathieu serves as Chief Executive Officer and President at Immunovia AB (publ) since June 02, 2022. Mr. Mathieu served as an Acting CEO & President of Immunovia AB (publ) since January 20, 2022...

Gruppo dirigente

Nome	Posizione	Mandato	Compensazione	Proprietà
Philipp Mathieu	CEO & President	less than a year	Nessun dato	0.0093% SEK 51.4k
Karin Liwendahl	Chief Financial Officer	less than a year	Nessun dato	Nessun dato
Jeff Borcherding	Chief Executive Officer of US	less than a year	Nessun dato	Nessun dato

1.0yrs

Durata media

Gestione esperta: Il team dirigenziale di IMMNOS non è considerato esperto (durata media 1 anni), il che suggerisce un nuovo team.

Membri del Consiglio di amministrazione

Nome	Posizione	Mandato	Compensazione	Proprietà
Carl Arne Borrebaeck	Independent Chairman of the Board	16yrs	SEK 580.00k	7.56% SEK 41.7m
Hans Johansson	Independent Director	6yrs	SEK 288.00k	0.14% SEK 761.7k
Margaret Tempero	Member of Scientific Advisory Board	6.6yrs	Nessun dato	Nessun dato
Philipp Sixt Von Hugo	Independent Director	less than a year	Nessun dato	Nessun dato
Diane Simeone	Member of Scientific Advisory Board	6.5yrs	Nessun dato	Nessun dato
Stephen Pereira	Member of Scientific Advisory Board	5.5yrs	Nessun dato	Nessun dato
Eric Krafft	Independent Director	less than a year	Nessun dato	Nessun dato
Peter Andersen	Independent Director	2.7yrs	SEK 268.00k	0.052% SEK 286.0k
Martin Moller	Director	1.7yrs	SEK 160.00k	0.0047% SEK 25.8k

5.5yrs

Durata media

66yo

Età media

Consiglio di amministrazione esperto: I membri del consiglio di amministrazione di IMMNOS sono considerati esperti (durata media dell'incarico 5.5 anni).

Immunovia Gestione

Gestione criteri di controllo 1/4

Informazioni chiave

Aggiornamenti recenti sulla gestione

Immunovia AB (Publ) Elects Melissa Farina and Valerie Bogdan-Powers as New Board Members

Immunovia AB (publ) Announces Board Changes

Immunovia AB (Publ) Announces Board Changes

Philipp Von Hugo Resigns from Immunovia's Board at His Own Request

Immunovia AB (Publ) Appoints Lara E. Sucheston-Campbell as the Head of Clinical and Medical Affairs, Effective February 1, 2023

Immunovia Inc. Appoints Jon Hager as New National Sales Director

Recent updates

Immunovia AB (Publ) Acquires All Blood Samples Required to Clinically Validate Its Next-Generation Test for Pancreatic Cancer

Immunovia Completes Analytical Validation of Its Next-Generation Pancreatic Cancer Test

Immunovia AB (publ) Announces the Next-Generation Test to Be Included in Large Study of Pancreatic Cysts funded by the U.S. National Institutes of Health

Immunovia Files US Patent Application to Protect Its Next-Generation Test

Immunovia Completes Development of Its Pancreatic Cancer Detection Test After Substantially Increasing Test Accuracy

Immunovia AB Presents Detailed Discovery Study Results for its Next-Generation Early Detection Test for Pancreatic Cancer at PancreasFest 2024 Annual Meeting

Immunovia AB (publ) to Report Fiscal Year 2024 Results on Feb 25, 2025

Immunovia Streamlines Lab Operations with Move to Research Triangle Park, North Carolina

Immunovia AB Announces Positive Results from the Model-Development Study for Its Next-Generation Pancreatic Cancer Detection Test

Immunovia Successfully Develops Assays to Measure Targeted Proteomedix for Its Next-Generation Pancreatic Cancer Test - Moving Forward Towards Model-Development Study

Immunovia AB (publ) to Report Q3, 2024 Results on Nov 14, 2024

Immunovia AB (Publ) Elects Melissa Farina and Valerie Bogdan-Powers as New Board Members

Immunovia Successfully Completes Discovery Phase of Next-Generation Test Development

Immunovia to Significantly Restructure to Focus Resources on its Next-Generation Blood Test for Pancreatic Cancer Detection

Immunovia AB (publ) Announces Board Changes

Immunovia AB (Publ) Announces Board Changes

Philipp Von Hugo Resigns from Immunovia's Board at His Own Request

Immunovia Realigning Swedish Operations with Strategic Priorities and its Focus on the US Commercialization of the Immray Pancan-D Test

Immunovia AB (Publ) Appoints Lara E. Sucheston-Campbell as the Head of Clinical and Medical Affairs, Effective February 1, 2023

Immunovia Inc. Appoints Jon Hager as New National Sales Director

Immunovia AB (publ), Annual General Meeting, Apr 27, 2023

Immunovia AB (Publ) Announces Appointment of Nomination Committee for the 2023 Annual General Meeting

Immunovia AB Announces Executive Management Team Appointments

Immunovia AB Announces Positive Update on Physician Experience Program with IMMrayTM PanCan-d

Immunovia AB Issues Preliminary Payment Rate Determination for IMMray PanCan-D Test

Immunovia, Inc. Receives Clinical and Public Health Laboratory License from California Dept of Public Health for IMMray Pancan-d Test

Immunovia AB Announces PanDIA-1 Study for Early Detection of Pancreatic Cancer in Newly Onset Type Diabetics Moves into Next Phase

Immunovia AB Announces Results from PanFAM-1 Study

Immunovia AB (publ) Announces Executive Changes

Immunovia Names Philipp Mathieu as Chief Executive Officer

Immunovia AB Appoints Natalie Carfora as Head of Market Access US Subsidiary

Immunovia AB (Publ) Announces Board Changes

Full year 2021 earnings: EPS in line with expectations, revenues disappoint

Independent Director recently bought kr186k worth of stock

Second quarter 2021 earnings released: kr2.18 loss per share (vs kr1.67 loss in 2Q 2020)

Immunovia AB (publ) Receives Approval to Begin Testing Patients for Pancreatic Cancer with the Immrayt Pancan-D Test

Iimmunovia AB (Publ) Publishes Data Sets on the Optimization Study and Commercial Test Model Study

Full year 2020 earnings released: kr6.84 loss per share (vs kr5.85 loss in FY 2019)

Revenue in line with expectations

Immunovia AB (publ) to Report Q1, 2021 Results on Apr 28, 2021

Immunovia's PanFAM Prospective Study Gathers over 3000 Familial Hereditary Pancreatic Cancer Risk Samples and Will Be Analysed in the Second Half of 2021

Immunovia AB Announces Results from Study in Their Development Pipeline

New 90-day low: kr111

Director recently bought kr144k worth of stock

New 90-day low: kr122

Immunovia AB (Publ) Announces Appointment of Members of Nomination Committee

Immunovia AB (publ) Announces Management Changes

Immunovia AB (Publ) Announces Completion of Analysis from the Immray Pancan-D Verification Study

Immunovia Announces Positive Results from the Immray Pancan-D Verification Study

Immunovia AB (Publ) Appoints Mats Grahn as New Member of the Board of Directors

Immunovia Announces CEO Transition, Effective November 1, 2020

AMMINISTRATORE DELEGATO

Mandato

Gruppo dirigente

Durata media

Membri del Consiglio di amministrazione

Durata media

Età media